Geriatric assessment in AML treatment selection may impact early mortality rates

SAN DIEGO — Personalizing treatment using both geriatric assessment and genetic profiling may decrease rates of early mortality among older patients with acute myeloid leukemia, according to a study from ASH Annual Meeting and Exposition.
“The trial had broad eligibility criteria and allowed patients with various comorbidities such as advanced liver or kidney problems or other concurrent malignancies to participate,” Vijaya Raj Bhatt, MBBS, MS, an associate professor and medical director of the leukemia program at University of Nebraska Medical Center, told Healio. “The

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.